Both lower blood glucose with a low risk of hypoglycemia, but GLP-1 RAs show greater efficacy, aid in weight loss, and improve cardiovascular factors [7]. The GLP-1 RA liraglutide is an innovative therapeutic option for glycaemic control with additional benefits in reducing body weight and the risk of cardiovascular events [8]. The gene discussed is GCG; the disease is Hypoglycemia.